Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food

British Journal of Clinical Pharmacology

Volumn 45, Issue 1, 1998, Pages 31-35

  Young, M A ^a   Lettis, S ^a   Eastmond, R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Food; Interaction; Pharmacokinetics; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; CHROMANS; CROSS-OVER STUDIES; DIGESTIVE SYSTEM; EATING; FOOD; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031907647     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00653.x     Document Type: Article

References (12)

1. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1547-1558.
2. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-bd/db mice. Metab 1995; 44: 486-490.
3. Horikoshi H, Fujiwara T, Yoshioka S, Wada M, Fukami M. Pharmacological characteristics of new antidiabetic agent CS-045 in diabetic animals. In Frontiers in Diabetes Research. Lessons from animal diabetes III ed. Shafrir H. Smith-Gordon v1.8: 1990; pp 320-324.
4. Ciaraldi T, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, A new antidiabetic agent. Metab 1990; 39: 1056-1062.
5. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
6. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
7. Horikoshi H, Yoshioka T, Kawasaki T, et al. Troglitazone (CS-045), a new antidiabetic drug. Ann Rep Sankyo Res Lab 1994; 46: 1-57.
8. Ritschel WA. Basic pharmacokinetics, 4th edition. Drug Intelligence Publications: Hamilton, IL; 1992; 116-122.
9. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics, 4th Edition. Lea and Febiger, Philadelphia, 1991: pp1-8.
10. Pabst G, Jaegar H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 38: 5-10.
11. Conover WJ (1988). Practical non-parametric statistics, 2nd edition. Wiley: New York; pp 288-290.
12. Williams L, Davis JA, Lowenthal DT. The influence of food on the absorption and metabolism of drugs. Clin Nutrition 1993; 77: 815-829.